July 31, 2014 11:31 PM ET


Company Overview of Constellation Pharmaceuticals, Inc.

Company Overview

Constellation Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops drugs in the field of epigenetics. The company develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders, and other diseases. Its drug discovery and development platform creates a pipeline of programs across the writer, eraser, and reader classes of epigenetic targets to develop new drugs in oncology, inflammation, and other therapeutic areas. Constellation Pharmaceuticals, Inc. has a strategic agreement with Genentech. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in April 2008. Constellation Phar...

215 First Street

Suite 200

Cambridge, MA 02142

United States

Founded in 2008





Key Executives for Constellation Pharmaceuticals, Inc.

Chief Executive Officer and President
Executive Chairman
Age: 52
Compensation as of Fiscal Year 2014.

Constellation Pharmaceuticals, Inc. Key Developments

Constellation Pharmaceuticals, Inc. Announces New Preclinical Data on Novel Bet Bromodomain Inhibitors

Constellation Pharmaceuticals, Inc. announced the publication of a study in the Journal of Experimental Medicine demonstrating that small molecule inhibitors selectively targeting BET bromodomains can suppress T helper 17 (T 17) differentiation and T 17-mediated pathology in models of autoimmune diseases. The paper appears in the online early edition of J Exp Med published on October 7, 2013. During the last decade, researchers have uncovered the importance of T 17 cells as an integral part of the immune system that protects the human body from infections. However, this research has also shown that, when pathologically activated, these cells can attack multiple organs in the body and trigger autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and psoriasis. Because of the important roles that T 17 cells play in both normal and dysregulated immune function, many academic, biotech and pharmaceutical laboratories have research programs devoted to targeting T 17 cells.

Constellation Pharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's East/West CEO Conference, Jan-06-2013 12:15 PM

Constellation Pharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's East/West CEO Conference, Jan-06-2013 12:15 PM. Venue: Four Seasons Hotel, San Francisco, California, United States. Speakers: Keith E. Dionne, Chief Executive Officer and President.

Constellation Pharmaceuticals, Inc. Enter into Strategic Partnership with The Leukemia & Lymphoma Society to Develop Novel Bet Inhibitor for the Treatment of Hematologic Malignancies

Constellation Pharmaceuticals, Inc. announced that it has entered into a strategic partnership with The Leukemia & Lymphoma Society(R) (LLS) to advance the development of a novel BET inhibitor for the treatment of patients with hematologic malignancies. Under the terms of the agreement, LLS will provide up to $7.5 million in funding to support Constellation's small molecule BET inhibitor program through the completion of a broad Phase 1 clinical plan. Taking an active role in accelerating development of novel therapies for patients, the LLS have committed funding to support this collaboration as part of its Therapy Acceleration Program (TAP). TAP is LLS's bold initiative designed to advance therapies with high prospects of providing benefit to patients suffering from blood cancers. By partnering directly with biotechnology companies, LLS is taking a results-oriented approach to more quickly identify potential breakthrough therapies and advance them along the FDA drug approval pathway.

Similar Private Companies By Industry

Company Name Region
Trigemina, Inc. United States
Orphan Medical Inc. United States
Miravant Pharmaceuticals Inc United States
Damage Control Technologies, Inc. United States
Dowpharma Contract Manufacturing Services United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Constellation Pharmaceuticals, Inc., please visit www.constellationpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.